This Key Event Relationship is licensed under the Creative Commons BY-SA license. This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
Relationship: 2312
Title
Binding to ACE2 leads to Downregulation of ACE2
Upstream event
Downstream event
AOPs Referencing Relationship
| AOP Name | Adjacency | Weight of Evidence | Quantitative Understanding | Point of Contact | Author Status | OECD Status |
|---|---|---|---|---|---|---|
| Viral spike protein interaction with ACE2 leads to microvascular dysfunction, via ACE2 dysregulation | adjacent | Brendan Ferreri-Hanberry (send email) | Under Development: Contributions and Comments Welcome | |||
| Binding of viral S-glycoprotein to ACE2 receptor leading to dysgeusia | adjacent | Moderate | Not Specified | Agnes Aggy (send email) | Under development: Not open for comment. Do not cite | Under Development |
Taxonomic Applicability
Sex Applicability
Life Stage Applicability
The current KER relates to evidence for downregulation of the ACE2 following the binding of the viral spike S protein of SARS-COV (1 or 2).
According to the evidence (mostly from the study of SARS-CoV-1 in the years preceding the SARS-CoV-2 emergence and the COVID-19 pandemic) the infection of cells by SARS-CoV leads to downregulation of ACE2, either:
- in the form of shedding of the ACE2 (which has other repercussions from a RAAS point of view)
- internalization / endocytosis of the ACE2
- downregulation of mRNA / protein expression.
The literature focusing on SARS-CoV-2 is quite scarce, especially in relation to animal work (only 5 studies have been identified) up to November 2021.
| ID | Experimental Design | Species | Upstream Observation | Downstream Observation | Citation (first author, year) | Notes |
|---|
| Title | First Author | Biological Plausibility |
Dose Concordance |
Temporal Concordance |
Incidence Concordance |
|---|